161 related articles for article (PubMed ID: 28880875)
21. Diagnosis of tuberculosis from smear-negative presumptive TB cases using Xpert MTB/Rif assay: a cross-sectional study from Nepal.
Khadka P; Thapaliya J; Basnet RB; Ghimire GR; Amatya J; Rijal BP
BMC Infect Dis; 2019 Dec; 19(1):1090. PubMed ID: 31888522
[TBL] [Abstract][Full Text] [Related]
22. Impact of Xpert MTB/RIF assay on multidrug-resistant tuberculosis treatment outcomes in a health district in South Africa.
Mahwire TC; Zunza M; Marukutira TC; Naidoo P
S Afr Med J; 2019 Mar; 109(4):259-263. PubMed ID: 31084692
[TBL] [Abstract][Full Text] [Related]
23. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF.
Ullah I; Javaid A; Masud H; Ali M; Basit A; Ahmad W; Younis F; Yasmin R; Khan A; Jabbar A; Husain M; Butt ZA
J Med Microbiol; 2017 Apr; 66(4):412-418. PubMed ID: 28425873
[TBL] [Abstract][Full Text] [Related]
24. Improving rifampicin-resistant tuberculosis diagnosis using Xpert
Dunbar R; Naidoo P; Beyers N; Langley I
Int J Tuberc Lung Dis; 2018 Aug; 22(8):890-898. PubMed ID: 29991398
[TBL] [Abstract][Full Text] [Related]
25. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
[TBL] [Abstract][Full Text] [Related]
26. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
[TBL] [Abstract][Full Text] [Related]
27. Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.
Lorent N; Kong C; Kim T; Sam S; Thai S; Colebunders R; Rigouts L; Lynen L
Int J Tuberc Lung Dis; 2015 Dec; 19(12):1528-35. PubMed ID: 26614197
[TBL] [Abstract][Full Text] [Related]
28. A cost-benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns.
Donkeng-Donfack VF; Tchatchueng-Mbougua JB; Abanda NN; Ongboulal SM; Djieugoue YJ; Kamdem Simo Y; Mekemnang Tchoupa M; Bekang Angui F; Kuate Kuate A; Mbassa V; Mvondo Abeng Belinga E; Eyangoh S
BMC Infect Dis; 2022 Mar; 22(1):219. PubMed ID: 35246071
[TBL] [Abstract][Full Text] [Related]
29. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
[TBL] [Abstract][Full Text] [Related]
31. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
[TBL] [Abstract][Full Text] [Related]
32. The New Xpert MTB/RIF Ultra: Improving Detection of
Chakravorty S; Simmons AM; Rowneki M; Parmar H; Cao Y; Ryan J; Banada PP; Deshpande S; Shenai S; Gall A; Glass J; Krieswirth B; Schumacher SG; Nabeta P; Tukvadze N; Rodrigues C; Skrahina A; Tagliani E; Cirillo DM; Davidow A; Denkinger CM; Persing D; Kwiatkowski R; Jones M; Alland D
mBio; 2017 Aug; 8(4):. PubMed ID: 28851844
[TBL] [Abstract][Full Text] [Related]
33. Comparing the impact of genotypic based diagnostic algorithm on time to treatment initiation and treatment outcomes among drug-resistant tuberculosis patients in Amhara region, Ethiopia.
Kassa GM; Merid MW; Muluneh AG; Wolde HF
PLoS One; 2021; 16(2):e0246938. PubMed ID: 33600409
[TBL] [Abstract][Full Text] [Related]
34. Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.
Nair SA; Raizada N; Sachdeva KS; Denkinger C; Schumacher S; Dewan P; Kulsange S; Boehme C; Paramsivan CN; Arinaminpathy N
PLoS One; 2016; 11(2):e0150054. PubMed ID: 26918818
[TBL] [Abstract][Full Text] [Related]
35. How has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?
Timire C; Takarinda KC; Harries AD; Mutunzi H; Manyame-Murwira B; Kumar AMV; Sandy C
Trans R Soc Trop Med Hyg; 2018 Jun; 112(6):285-293. PubMed ID: 29992299
[TBL] [Abstract][Full Text] [Related]
36. Improved case detection using Xpert
Kanade SR; Nataraj G; Mehta PR
Indian J Med Microbiol; 2018; 36(4):590-593. PubMed ID: 30880713
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of the performance of InnowaveDX MTB/RIF for the detection of
Wang YP; Tan YH; Li X; Wang J; Chen CG; Xu J; Xiang J
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Jul; 46(7):658-663. PubMed ID: 37402655
[No Abstract] [Full Text] [Related]
38. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis value with Xpert Mtb/RIF assay for cervical tuberculous lymphadenitis].
Yang CQ; Liu XY; Du RH; Cao TZ; Dai XY
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 31(17):1338-1340. PubMed ID: 29798226
[No Abstract] [Full Text] [Related]
40. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
